| May 28 |
Merus’ Petosemtamab in Combination with Pembrolizumab Interim Data Demonstrates Robust Response Rate and Favorable Safety Profile in 1L r/m HNSCC
|
| May 27 |
Merus (MRUS) Surges 36% on Head & Neck Cancer Antibody Data
|
| May 24 |
Why Is Cancer-Focused Merus Stock Trading Over 30% On Friday?
|
| May 24 |
Merus Clears Wall Street's Bar With Cancer Data
|
| May 24 |
Merus Stock: Priced High After An ASCO Surprise Surge (Maintain Buy)
|
| May 24 |
Merus Rallies Ahead of Upcoming Presentations for Prospective Cancer Treatments, Price Target Boost at BoA Securities
|
| May 24 |
Cancer Biotech Stocks Are on the Move Ahead of a Big Event. What to Know.
|
| May 24 |
Why Top 4% Biotech Stock, Merus, Just Catapulted To A Record High
|
| May 24 |
Merus rallies on publication of oncology study abstracts
|
| May 24 |
ASCO 2024: Merus touts positive Phase II data for head and neck cancer antibody
|
